FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| cabazitaxel | Prostate Cancer | PHASE3 | COMPLETED |
| TOCOSOL Paclitaxel | Breast Neoplasm | PHASE3 | TERMINATED |
| Taxol | Breast Neoplasm | PHASE3 | TERMINATED |
| Custirsen | Non-Small Cell Lung Cancer | PHASE3 | COMPLETED |
| Prednisone | Prostate Cancer | PHASE3 | COMPLETED |
| custirsen sodium | Prostate Cancer | PHASE3 | COMPLETED |
| Dexamethasone | Prostate Cancer | PHASE3 | COMPLETED |
| Docetaxel | Castrate-Resistant Prostate Cancer | PHASE3 | TERMINATED |
| isotonic, 0.9% sodium chloride | Castrate-Resistant Prostate Cancer | PHASE3 | TERMINATED |
| TOCOSOL(R) Paclitaxel | Breast Cancer | PHASE2 | COMPLETED |
ACHV holds $28.1M in cash and burns about $12.5M/quarter from operations, giving an estimated runway of 6.8 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ACHV free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-06-02 | Farrow Jeffrey S |
Purchase | $0 |
| 2026-06-02 | Waldman Reid Alexander |
Purchase | $0 |
| 2026-05-13 | Martin Christopher Nathan |
Purchase | $0 |
| 2026-04-21 | Goldberg Andrew D. |
Purchase | $0 |
| 2026-04-21 | Goldberg Andrew D. |
Purchase | $0 |
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-06-20 | — | NDA | +9% | — | — |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ACHV and 2 more tickers of your choice.
Create Free Account →